Why Certara Inc. (CERT) Soared Last Week?

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other firms that defied the market slump and recorded double-digit gains last week.

The stock market may have taken a beating for most of the week, but it was able to recover losses on Friday, as investors gobbled up shares while weighing the impact of the US-China trade war.

Among all major indices, the tech-heavy Nasdaq registered the highest gain, up 7.29 percent, followed by the S&P 500 with 5.7 percent, and the Dow Jones by 4.95 percent.

Ten companies, predominantly in the gold and biopharmaceutical sectors, were the week’s top performers as investors sought haven from their stocks amid market uncertainties.

In this article, we have identified last week’s 10 highest gainers and detailed the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million trading volume.

The week-on-week prices were based on the companies’ closing prices on Friday as against on April 4, or a week earlier.

Certara Inc. (NASDAQ:CERT)

Certara Inc. grew its share prices by 35.18 percent last week to finish at $12.91 each on Friday versus the $9.55 on April 4 following news that it released a new version of the Simcyp Simulator to support physiologically-based pharmacokinetic (PBPK) modeling, which can forecast the behavior of drugs in various body tissues.

According to CERT, the latest version would strengthen its position as a leader in the PBPK modeling in drug development and regulatory decision-making.

In the fourth quarter of 2024, CERT swung to a net income of $6.6 million from a net loss of $12.5 million in the same period a year earlier. Revenues increased by 14 percent to $100.4 million from $88 million year-on-year.

For this year, CERT expects revenues to settle between $415 million and $425 million as well as earnings per share of $0.42 to $0.46 each.

CERT accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Overall, CERT ranks 2nd on our list of firms that defied the market slump and recorded double-digit gains last week. While we acknowledge the potential of CERT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is as promising as CERT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.